Istaroxime manufacturers
- Istaroxime
-
- $15.00 / 1KG
-
2021-07-13
- CAS:203737-93-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
- Istaroxime
-
- $15.00 / 1KG
-
2021-07-10
- CAS:203737-93-3
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
| | Istaroxime Basic information |
| Product Name: | Istaroxime | | Synonyms: | Istaroxime;PST 2744;PST2744;PST-2744;PST2744/PST-2744;CS-1089;Istaroxime(PST2744);(3E,5S,8R,9S,10R,13S,14S)-3-(2-aminoethoxyimino)-10,13-dimethyl-1,2,4,5,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-6,17-dione | | CAS: | 203737-93-3 | | MF: | C21H32N2O3 | | MW: | 360.5 | | EINECS: | | | Product Categories: | | | Mol File: | 203737-93-3.mol |  |
| | Istaroxime Chemical Properties |
| Boiling point | 511.1±60.0 °C(Predicted) | | density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in H2O | | form | Powder | | pka | 9.49±0.10(Predicted) |
| | Istaroxime Usage And Synthesis |
| Biological Activity | istaroxime is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (na+/k+ atpase). istaroxime is an investigational drug originally patented and developed by the italian pharmaceutical company sigma-tau. istaroxime is now under development for treatment of acute decompensated heart failure by cvie therapeutics. | | in vitro | pst2744 inhibited the na+/k+-atpase activity from dog kidney with an ic50 value of 0.43 ± 0.15 μm [1]. the transient inward current (i(ti)) induced by a ca(2+) transient in the presence of complete na(+)/k(+) pump blockade was inhibited (-43%) by pst2744 but not by digoxin [2]. | | in vivo | intravenous infusion of 0.2 mg/kg/min pst2744 in anesthetized guinea pigs exerted an immediate and long-lasting inotropic effect (ed(80) of 1.89 +/- 0.37 mg/kg) without causing lethal arrhythmias up to a cumulative dose of 18 mg/kg [1]. istaroxime intravenous infusion (0.11 mg/kg per min) significantly increased both indices of contraction and relaxation (fractional shortening, +18+/-3.7%; aortic flow rate, +19+/-2.9%; peak myocardial systolic velocity, +36+/-7%; circumferential fiber shortening, +24+/-4.1%; peak atrial flow velocity, +69+/-8.6%; isovolumic relaxation time, +19+/-6.9%; and peak myocardial early diastolic velocity, +42+/-12%) [3]. in 5 animals, pst-2744 effects were compared with dobutamine. heart rates, pr intervals and qt intervals were unchanged following pst-2744 administration. pst-2744 increased contractility (+dp/dt) by 56% from 1881 +/- 282 mm hg/s to 2939 +/- 734 mm hg/s (p < 0.01) [4]. | | IC 50 | 0.43 ± 0.15 μm (na+/k+-atpase activity from dog kidney) [1] |
| | Istaroxime Preparation Products And Raw materials |
|